Understanding and Addressing Hepatitis C Reinfection in the Oral Direct-Acting Antiviral Era

What factors are associated with HCV reinfection and how can reinfection risk be minimized?
Understanding and Addressing Hepatitis C Reinfection in the Oral Direct-Acting Antiviral Era
O. Falade-Nwulia; M. S. Sulkowski; A. Merkow; C. Latkin; S. H. Mehta J Viral Hepat. 2018;25(3):220-227. Abstract and Introduction

Abstract
The availability of effective, simple, well-tolerated oral direct-acting antiviral (DAA) hepatitis C regimens has raised optimism for hepatitis C virus (HCV) elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM) however threatens the achievement of this goal from a patient, provider and population perspective. The goal of this review was to synthesize our current understanding of estimated rates and factors associated with HCV reinfection. This review also proposes interventions to aid understanding of and reduce hepatitis C reinfection among PWID and HIV-infected MSM in the oral direct-acting antiviral era.

Full text available at: Medscape
Free registration may be required